Atlas FDA

STAARVISC II & SHELLGEL SODIUM HYAURONATE

FDA premarket approval P000046/S015 · decided 2012-03-27

Approval details

PMA number
P000046
Supplement
S015
Supplement type
Normal 180 Day Track
Supplement reason
Change Design/Components/Specifications/Material
Trade name
STAARVISC II & SHELLGEL SODIUM HYAURONATE
Generic name
AID, SURGICAL, VISCOELASTIC
Applicant
Anika Therapeutics, Inc.
Date received
2009-05-27
Decision date
2012-03-27
Days to decision
1035 days
Decision code
APPR
Product code
LZP
Advisory committee
Ophthalmic
Expedited review
No
Location
Beford, MA
Statement
APPROVAL FOR A MANUFACTURING SITE CHANGE FROM THE PREVIOUS FACILITY IN WEST CUMMINGS PARK, WOBURN, MASSACHUSETTS TO THE NEW FACILITY LOCATED IN BEDFORD, MASSACHUSETTS. IN ADDITION, THE SUPPLEMENT REQUESTED APPROVAL TO CHANGE THE TERMINAL STERILIZATION METHOD OF THE PRODUCT FROM E-BEAM CONTROLLED DEPTH STERILIZATION TO VAPORIZED HYDROGEN PEROXIDE (VHP) GAS STERILIZATION.

Class III intelligence, same tools

PMAs share the API, exports and alerts with 510(k) data - watch an applicant and hear about every approval.

510(k) clearances by this applicant

RecordFirmDate
Integrity™ Implant (K250997)Anika Therapeutics, Inc.2025-06-17
Tactoset® Injectable Bone Substitute (K231968)Anika Therapeutics, Inc.2023-12-20
Integrity Implant (K223538)Anika Therapeutics, Inc.2023-08-17
Integrity™ Bone Staple Fixation System (K223860)Anika Therapeutics, Inc.2023-05-22
Anika Tissue Tack Fixation System (K222487)Anika Therapeutics, Inc.2023-05-08
Tactoset (K223915)Anika Therapeutics, Inc.2023-03-29
Tactoset Injectable Bone Substitute (K212083)Anika Therapeutics, Inc.2021-08-31
SCS 17-01 (K190956)Anika Therapeutics, Inc.2020-01-30